|
| |
The CNS Market Outlook to 2009 Thursday 1st of January 1970 1:00
The
CNS Market Outlook to 2009
The management report 'The CNS Market Outlook to
2009' provides in-depth analysis of the current growth opportunities, threats,
leading players and their future prospects; it will enable you to understand the
most attractive market sectors and discover what will influence competitive
strategy and franchise development. As traditional markets stagnate, many major
pharmaceutical companies have been slow to seize opportunities to develop
markets and key growth indications. At the same time, increased pricing pressure
from generic competition and limited differentiation among new medicines will
see some major players facing disappointing performances and prompting strategic
changes. Identify the potential growth areas within key CNS markets
(Alzheimer’s disease, depression, epilepsy, migraine, multiple sclerosis,
pain, Parkinson’s disease and schizophrenia) and formulate the most effective
future strategy for your company to reduce resource wastage.
Sept 2004
248 pages
PDF format
Table of Contents
The CNS Market Outlook to 2009
Executive Summary 14
Patient potential 14
Global market analysis 15
Global players in the CNS market 16
Development of key market segments to 2009 17
Chapter 1 Patient potential 20
Summary 20
Introduction 21
Alzheimer’s disease 23
Background 23
Prevalence 24
Depression 25
Background 25
Depression and co-morbidities 26
Prevalence 28
US 28
Western Europe 29
Japan 30
Pediatric prevalence 31
Epilepsy 32
Patient potential 33
Multiple sclerosis (MS) 34
Background 34
Patient potential 36
Pain 38
Post-operative pain 39
Cancer pain 40
Neuropathic lower back pain 41
HIV-related pain 42
Fibromyalgia 42
Arthritic pain 44
Patient potential 44
Schizophrenia 47
Prevalence of schizophrenia 48
Migraine 49
Patient potential 50
Parkinson’s disease 51
Patient potential 52
Genetic factors 52
Environmental factors 53
Geographical differences 53
Prevalence 53
Chapter 2 Global market analysis 56
Summary 56
Migraine 57
Rx market overview 57
Drug analysis 59
Other Rx drugs 63
Epilepsy 67
Market overview 68
Traditional anti-convulsants 69
Competitive overview 70
Drug analysis 71
Second-generation anti-convulsants 74
Competitive overview 74
Drug analysis 75
Multiple Sclerosis 81
Market overview 82
Drug analysis 84
Alzheimer’s disease 91
Drug analysis 93
Depression 100
Market overview 101
Serotonergics 104
Competitive overview 105
Drug analysis 106
TCAs 113
Competitive overview 113
Noradrenergics 114
Competitive overview 114
Drug analysis 115
MAOIs and ‘Others’ 118
Competitive overview 119
Drug analysis 119
Parkinson’s Disease 121
Market overview 122
Dopaminergics 124
Competitive overview 125
Drug analysis 125
Dopamine agonists 127
Competitive overview 127
Drug analysis 128
MAOIs 133
Competitive overview 134
Anticholinergics 134
Competitive overview 134
COMT inhibitors 135
Competitive overview 135
Drug analysis 136
Schizophrenia 137
Competitive overview 139
Drug analysis 140
Pain 148
Overview 148
Market overview 148
NSAIDs market overview 149
NSAID drug analysis 150
Opioids 157
Opioid drug analysis 158
Chapter 3 Global players in the CNS Market 162
Summary 162
Introduction 163
Pfizer 165
Marketed products 165
R&D compounds 166
Asenapine 166
Sumanirole 167
Indiplon 168
CP-526,555 170
P57 170
PNU-170,413 171
CNS portfolio sales forecasts and forecast revenue growth 172
GlaxoSmithKline 173
Marketed products 173
R&D compounds 174
Avandia (rosiglitazone) 175
Talnetant 175
353162 175
CNS portfolio sales forecasts and forecast revenue growth 176
Johnson & Johnson 177
Marketed products 177
R&D compounds 177
CNS portfolio sales forecasts and forecast revenue growth 178
Eli Lilly 179
Marketed products 179
R&D compounds 180
Cymbalta (duloxetine) 180
CNS portfolio sales forecasts and forecast revenue growth 182
Wyeth 183
Marketed products 183
R&D compounds 184
DVS-233 184
CCI-779 185
SRA-333 and AAB-001 185
CNS portfolio sales forecasts and forecast revenue growth 186
AstraZeneca 187
Marketed products 187
R&D compounds 188
Cerovive 188
AR-A2 189
CNS portfolio sales forecasts and forecast revenue growth 189
Sanofi-Synthélabo 190
Marketed products 190
R&D compounds 191
Xaliproden 192
SR 58611 193
Rimonabant 193
Eplivanserin and osanetant 194
Saredutant 195
SL-65.1498 196
CNS portfolio sales forecasts and forecast revenue growth 196
Abbott 197
Marketed products 197
R&D compounds 197
ABT-834, ABT-894 198
CNS portfolio sales forecasts and forecast revenue growth 198
Forest Labs 199
Marketed products 199
R&D compounds 200
Acamprosate 200
Neramexane 202
CNS portfolio sales forecasts and forecast revenue growth 203
Novartis 204
Marketed products 204
R&D compounds 205
TCH346 205
AMP397 205
CNS portfolio sales forecasts and forecast revenue growth 206
Chapter 4 Development of key CNS
markets to 2009 208
Summary 208
Introduction 209
Markets analyzed 209
Methodology 210
Quantifying market unmet needs 210
Quantifying competitive intensity 210
Quantifying market attractiveness 211
Alzheimer’s disease 213
Overview 213
Forthcoming launches 214
Phase II pipeline activity 215
New products 216
Ebixa/Namenda (memantine) 216
Unmet needs 217
Rating 218
Competitive intensity 219
Market share of current leading products in 2009 219
Generic competition 219
Players in 2009 220
Market attractiveness 220
Patient potential 220
Antipsychotics 222
Overview 222
Unmet Needs 222
Rating 224
Competitive intensity in 2009 224
Market share of current leading products in 2009 224
Generic competition 224
Late stage pipeline activity 225
Phase II pipeline activity 225
Players in 2009 226
Market attractiveness 227
Patient potential 227
Multiple Sclerosis 228
Overview 228
Unmet needs 229
Rating 230
Competitive intensity in 2009 230
Market share of current leading products in 2009 230
Generic competition 231
Late stage pipeline activity 231
Players in 2009 232
Market attractiveness 233
Patient potential 233
Pain 234
Overview 234
Market unmet needs 234
Efficacy 234
Side-effects 235
NSAIDS 235
Opioids 235
Drug delivery formulations 236
Rating 237
Competitive intensity 237
Market share of current leading products in 2009 237
Generic competition 237
Late stage pipeline activity 238
Players in 2009 239
Market attractiveness 240
Patient potential 240
Comparative analysis 241
Comparison of market unmet needs 241
Comparison of competitive intensity in 2009 242
Comparison of market attractiveness 243
Summary of commercial viability 243
Index 244
List of Figures
Figure 1.1: Common psychiatric conditions that are co-morbid with MDD 26
Figure 1.2: MDD and anxiety disorders – patient population, 2003 28
Figure 1.3: Prevalence of major indications associated with pain, 2003 39
Figure 2.4: Market share of the leading migraine therapies, 2003 58
Figure 2.5: Triptan formulations by brand, 2003 59
Figure 2.6: Market share of the leading anticonvulsant therapies, 2003 69
Figure 2.7: Market share of the leading MS therapies, 2003 83
Figure 2.8: Market share of the leading AD therapies, 2003 92
Figure 2.9: Historical evolution of the anti-depressants 101
Figure 2.10: Market share of the leading MDD therapies, 2003 102
Figure 2.11: Market share of the leading PD therapies, 2003 123
Figure 2.12: Market share of leading Schizophrenia therapies, 2003 139
Figure 2.13: Market share of leading Pain therapies, 2003 149
Figure 3.14: Competitive dynamics between leading players in the global CNS
market, 2002–03
164
Click title to order: The
CNS Market Outlook to 2009
To order these
reports contact peter.barfoot@bioportfolio.com or
telephone +44 1300 321501 or +1 415 680 2472 and a representative will get back
to you.
You can also
order on line at: http://www.bioportfolio.com/cgi-bin/acatalog/search.html
Browse other news from this organisation: Datamonitor
Related Web-Links(If any, Generated Automatically)
Download PDF 
|
